Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants

References

• Borissoff JI, Spronk HM, Ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Eng J Med 2011;364:1746–1760.
   PubMed Web of Science ®Google Scholar
• Papadaki S, Tselepis AD. Nonhemostatic activities of factor xa: are there pleiotropic effects of anti-fxa direct oral anticoagulants? Angiology 2019;70:896–907.
   PubMed Web of Science ®Google Scholar
• Spronk HM, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, Ten Cate H. Pleiotropic effects of factor xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res 2014;101:344–351.
   PubMed Web of Science ®Google Scholar
• Moschonas IC, Kellici TF, Mavromoustakos T, Stathopoulos P, Tsikaris V, Magafa V, Tzakos AG, Tselepis AD. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand. Platelets 2017;28:812–821.
   PubMed Web of Science ®Google Scholar
• Borensztajn K, Peppelenbosch MP, Spek CA. Factor xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008;14:429–440.
   PubMed Web of Science ®Google Scholar
• Kalz J, Ten CH, Spronk HM. Thrombin generation and atherosclerosis. J Thromb Thrombolysis 2014;37:45–55.
   PubMed Web of Science ®Google Scholar
• Stavenuiter F, Mosnier LO. Noncanonical par3 activation by factor xa identifies a novel pathway for tie2 activation and stabilization of vascular integrity. Blood 2014;124:3480–3489.
   PubMed Web of Science ®Google Scholar
• Busch G, Seitz I, Steppich B, Hess S, Eckl R, Schomig A, Ott I. Coagulation factor xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005;25:461–466.
   PubMed Web of Science ®Google Scholar
• Daubie V, Cauwenberghs S, Senden NH, Pochet R, Lindhout T, Buurman WA, Heemskerk JW. Factor xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta 2006;1763:860–869.
   PubMed Web of Science ®Google Scholar
• Senden NH, Jeunhomme TM, Heemskerk JW, Wagenvoord R, Van’t Veer C, Hemker HC, Buurman WA. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998;161(8):4318–4324.
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, Kaplanski S, Farnarier C. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (icam-1; cd54) and vascular cell adhesion molecule-1 (vcam-1; cd106). Blood 1998;92:1259–1267.
   PubMed Web of Science ®Google Scholar
• Jiang R, Wang NP, Tanaka KA, Levy JH, Guyton RA, Zhao ZQ, Vinten-Johansen J. Factor xa induces tissue factor expression in endothelial cells by p44/42 mapk and nf-kappab-dependent pathways. J Surg Res 2011;169:319–327.
   PubMed Web of Science ®Google Scholar
• Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC. Thrombin-dependent nf-{kappa}b activation and monocyte/endothelial adhesion are mediated by the carma3.Bcl10.Malt1 signalosome. J Biol Chem 2010;285:41432–41442.
   PubMed Web of Science ®Google Scholar
• Loeffen R, Spronk HM, Ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 2012;10:1207–1216.
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin k antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968–1975.
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Nielsen C, Soderstrom AC, Brandes A, Nybo M. Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis 2017;44:216–222.
   PubMed Web of Science ®Google Scholar
• Kim JB, Joung HJ, Lee JM, Woo JS, Kim WS, Kim KS, Lee KH, Kim W. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (prefer-af): study protocol for a randomized controlled trial. Trials 2016;17:422.
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Camoin-Jau L, Frere C. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment. J Thromb Haemost 2017;15:1522–1523.
   PubMed Web of Science ®Google Scholar
• Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801–1809.
   PubMed Web of Science ®Google Scholar
• Tura O, Skinner EM, Barclay GR, Samuel K, Gallagher RC, Brittan M, Hadoke PW, Newby DE, Turner ML, Mills NL. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013;31:338–348.
   PubMed Web of Science ®Google Scholar
• Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B. Endothelial outgrowth cells are not derived from cd133+ cells or cd45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007;27:1572–1579.
   PubMed Web of Science ®Google Scholar
• Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005;112:1618–1627.
   PubMed Web of Science ®Google Scholar
• Smadja DM, Bieche I, Silvestre JS, Germain S, Cornet A, Laurendeau I, Duong-Van-Huyen JP, Emmerich J, Vidaud M, Aiach M, et al. Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler Thromb Vasc Biol 2008;28:2137–2143.
   PubMed Web of Science ®Google Scholar
• Papadaki S, Sidiropoulou S, Chantzichristos V, Paschopoulos M, Tselepis A. Effect of thrombin on human endothelial projenitor cells. Hell J Atherosclerosis 2017;8:16–23.
   Google Scholar
• Chantzichristos VG, Gkrozou F, Stellos K, Paschopoulos ME, Tselepis AD. Comparative anti-platelet profiling reveals a potent anti-aggregatory effect of cd34+ progenitor cell-derived late-outgrowth endothelial cells in vitro. J Vasc Res 2018;55:13–25.
   PubMed Web of Science ®Google Scholar
• Guitton C, Cottereau A, Gerard N, Quillard T, Chauveau A, Devalliere J, Tonnerre P, Charreau B. Protective cross talk between activated protein c and tnf signaling in vascular endothelial cells: implication of epcr, noncanonical nf-kappab, and erk1/2 map kinases. Am J Physiol 2011;300:C833–842.
   PubMed Web of Science ®Google Scholar
• Bae JS, Rezaie AR. Thrombin inhibits nuclear factor kappab and rhoa pathways in cytokine-stimulated vascular endothelial cells when epcr is occupied by protein c. Thromb Haemost 2009;101:513–520.
   PubMed Web of Science ®Google Scholar
• Moschonas IC, Goudevenos JA, Tselepis AD. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Int J Cardiol 2015;185:9–18.
   PubMed Web of Science ®Google Scholar
• Kvasnicka T, Malikova I, Zenahlikova Z, Kettnerova K, Brzezkova R, Zima T, Ulrych J, Briza J, Netuka I, Kvasnicka J. Rivaroxaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 2017;18:636–642.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yao K, Ren L, Chen T, Yao D. Protective effect of astragalus polysaccharide on endothelial progenitor cells injured by thrombin. Int J Biol Macromol 2016;82:711–718.
   PubMed Web of Science ®Google Scholar
• Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, Utsunomiya K. Thrombin induces mcp-1 expression through rho-kinase and subsequent p38mapk/nf-kappab signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun 2011;411:798–803.
   PubMed Web of Science ®Google Scholar
• Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and par-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 2006;4:656–663.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ip JE, Huang J, Zhang L, Matsushita K, Liew CC, Pratt RE, Dzau VJ. Essential role of icam-1/cd18 in mediating epc recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res 2006;99:315–322.
   PubMed Web of Science ®Google Scholar
• Yadav A, Saini V, Arora S. Mcp-1: chemoattractant with a role beyond immunity: A review. Clin Chim Acta 2010;411:1570–1579.
   PubMed Web of Science ®Google Scholar
• Sanada F, Taniyama Y, Muratsu J, Otsu R, Iwabayashi M, Carracedo M, Rakugi H, Morishita R. Activated factor x induces endothelial cell senescence through igfbp-5. Sci Rep 2016;6:35580.
   PubMed Web of Science ®Google Scholar
• Ebrahimi S, Rezaei S, Seiri P, Ryzhikov M, Hashemy SI, Hassanian SM. Factor xa signaling contributes to the pathogenesis of inflammatory diseases. J Cell Physiol 2017;232:1966–1970.
   PubMed Web of Science ®Google Scholar
• Popovic M, Smiljanic K, Dobutovic B, Syrovets T, Simmet T, Isenovic ER. Thrombin and vascular inflammation. Mol Cell Biochem 2012;359:301–313.
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. Contributions from receptorsother than par1 include the transactivation of par2 by thrombin-cleaved par1. J Biol Chem 2000;275:13502–13509.
   PubMed Web of Science ®Google Scholar
• Hamilton JR, Frauman AG, Cocks TM. Increased expression of protease-activated receptor-2 (par2) and par4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to par2 and par4 agonists. Circ Res 2001;89:92–98.
   PubMed Web of Science ®Google Scholar
• Megyeri M, Mako V, Beinrohr L, Doleschall Z, Prohaszka Z, Cervenak L, Zavodszky P, Gal P. Complement protease masp-1 activates human endothelial cells: par4 activation is a link between complement and endothelial function. J Immunol 2009;183:3409–3416.
   PubMed Web of Science ®Google Scholar
• Fortunato TM, Vara DS, Wheeler-Jones CP, Pula G. Expression of protease-activated receptor 1 and 2 and anti-tubulogenic activity of protease-activated receptor 1 in human endothelial colony-forming cells. PloS One 2014;9:e109375.
   PubMed Web of Science ®Google Scholar
• Ellinghaus P, Perzborn E, Hauenschild P, Gerdes C, Heitmeier S, Visser M, Summer H, Laux V. Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res 2016;142:44–51.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA, Blessing E. Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban. Mediators Inflamm 2011;2011:432080.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Tsukahara K, Sakamaki K, Morita Y, Takamura T, Fukui K, Endo T, Shimizu M, Sawada R, Sugano T, et al. Comparison of anti-inflammatory effects of rivaroxaban vs. Dabigatran in patientswith non-valvular atrial fibrillation (rival-af study): multicenter randomized study. Heart Vessels 2019;34:1002–1013.
   PubMed Web of Science ®Google Scholar
• Wu TC, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Lin SJ, Chen JW. Rivaroxaban, a factor xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol 2015;14:81.
   PubMed Web of Science ®Google Scholar
• Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis 2018;46:393–398.
   PubMed Web of Science ®Google Scholar
• Achilles A, Mohring A, Dannenberg L, Grandoch M, Hohlfeld T, Fischer JW, Levkau B, Kelm M, Zeus T, Polzin A. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. J Thromb Haemost 2017;15:473–476.
   PubMed Web of Science ®Google Scholar